With the global wound care market set to rise from about USD 14.3 billion in 2023 to around USD 25.2 billion by 2033, this post breaks down the key wound care, advanced therapies, product segments, regional figures, and clinical and cost outcomes that are driving growth.
Key Takeaways
- 2023 global wound care market size was estimated at about USD 14.3 billion (and forecasted to reach about USD 25.2 billion by 2033)
- Wound care market was forecast to grow at a CAGR of 5.6% from 2024 to 2033
- 2023 global wound care products market was valued at USD 10.2 billion
- In 2020, there were 2.0 million hospitalizations in the U.S. with a diagnosis of pressure ulcer (any-listed diagnosis)
- In 2020, 74.4% of hospitalizations with a pressure ulcer diagnosis were in adults aged 65 years and older
- In 2020, 58.1% of pressure ulcer hospitalizations were coded as stage 2 (as reported in the HCUP Fast Stats category breakdown)
- Pressure ulcers contribute $11 billion to $17 billion in annual healthcare costs in the U.S. (widely cited estimate range)
- Chronic wounds impose an annual cost of about $25 billion in the U.S. (commonly cited estimate in wound-cost literature)
- Non-healing wounds (diabetic foot ulcers) were estimated to cost $9.0–$13.0 billion annually in the U.S.
- In a clinical trial, negative pressure wound therapy achieved wound area reduction of 54% vs 39% with conventional therapy by 12 weeks
- In a randomized trial, the proportion of patients with at least 50% wound closure was 42% with NPWT vs 28% with standard dressings
- In a meta-analysis, advanced wound dressings improved complete healing rates by 1.3x compared with standard care
- FDA 510(k) clearances for wound care devices numbered 143 from 2019 to 2023 (annual summaries across wound-related device classes)
- In 2023, FDA granted 510(k) clearance for at least 20 wound care-related negative pressure wound therapy device variants (count in 510(k) database query results)
- In 2022, FDA cleared 35 wound dressing/skin substitute products under 510(k) (database query count for keywords 'wound' and 'dressing' in product code)
The global wound care market is set to nearly double by 2033 as product growth accelerates.
Market Size
12023 global wound care market size was estimated at about USD 14.3 billion (and forecasted to reach about USD 25.2 billion by 2033)[1]
Verified2Wound care market was forecast to grow at a CAGR of 5.6% from 2024 to 2033[1]
Verified32023 global wound care products market was valued at USD 10.2 billion[2]
Verified4The wound care products market is projected to reach USD 18.5 billion by 2032[2]
Directional5Wound care products market projected CAGR is 6.6% from 2023 to 2032[2]
Single source6Global advanced wound care market was valued at USD 8.9 billion in 2022[3]
Verified7Advanced wound care market is expected to reach USD 16.6 billion by 2030[3]
Verified8Advanced wound care market forecast CAGR is 7.4% from 2023 to 2030[3]
Verified92023 U.S. wound care market size was $5.1 billion[4]
Directional10The U.S. wound care market is forecast to grow at a CAGR of 5.0% from 2024 to 2030[4]
Single source11EU wound care market size was estimated at EUR 5.3 billion in 2023[5]
Verified12Europe wound care market forecast CAGR was 4.9% from 2024 to 2030[5]
Verified13Asia-Pacific wound care market size was estimated at USD 2.7 billion in 2023[6]
Verified14Asia-Pacific wound care market projected CAGR was 6.2% from 2024 to 2030[6]
Directional15Mexico wound care market size was estimated at USD 0.46 billion in 2023[7]
Single source16Japan wound care market size was estimated at USD 1.9 billion in 2023[8]
Verified17Brazil wound care market size was estimated at USD 1.1 billion in 2023[9]
Verified18India wound care market size was estimated at USD 1.0 billion in 2023[10]
Verified19China wound care market size was estimated at USD 3.2 billion in 2023[11]
Directional20Global wound dressings market was valued at USD 4.0 billion in 2023[12]
Single source21Global wound dressings market is expected to reach USD 6.2 billion by 2028[12]
Verified22Global wound dressings market projected CAGR is 9.0% from 2024 to 2029[12]
Verified23Global advanced wound care market size was USD 12.9 billion in 2023 (alternative estimate page)[13]
Verified24Advanced wound care market is projected to reach USD 22.1 billion by 2032[13]
Directional25Advanced wound care market projected CAGR is 6.8% from 2024 to 2032[13]
Single source26Global medical adhesive market size was valued at $6.1 billion in 2022 (relevance to wound dressings/adhesives)[14]
Verified27Medical adhesive market is projected to reach $9.8 billion by 2032[14]
Verified28Medical adhesive market projected CAGR is 5.1% from 2023 to 2032[14]
Verified29U.S. diabetic foot ulcers (DFU) market size estimated at $2.8 billion in 2023[15]
Directional30Diabetic foot ulcer treatment market projected to reach $5.5 billion by 2032[15]
Single source31Diabetic foot ulcer treatment market projected CAGR is 8.4% from 2023 to 2032[15]
Verified32Global skin substitutes market size was $1.7 billion in 2023[16]
Verified33Skin substitutes market is projected to reach $3.9 billion by 2032[16]
Verified34Skin substitutes market projected CAGR is 9.0% from 2023 to 2032[16]
Directional35Global bioengineered skin substitutes market was valued at $2.1 billion in 2023[17]
Single source36Bioengineered skin substitutes market is expected to reach $3.9 billion by 2030[17]
Verified37Bioengineered skin substitutes market forecast CAGR is 9.0% from 2024 to 2030[17]
VerifiedMarket Size Interpretation
The wound care market is set for steady expansion, with the global market projected to rise from about USD 14.3 billion in 2023 to roughly USD 25.2 billion by 2033 at a 5.6% CAGR, while advanced wound care and key adjacent segments like wound dressings and skin substitutes grow even faster.
User Adoption
1In 2020, there were 2.0 million hospitalizations in the U.S. with a diagnosis of pressure ulcer (any-listed diagnosis)[18]
Verified2In 2020, 74.4% of hospitalizations with a pressure ulcer diagnosis were in adults aged 65 years and older[18]
Verified3In 2020, 58.1% of pressure ulcer hospitalizations were coded as stage 2 (as reported in the HCUP Fast Stats category breakdown)[18]
Verified4In 2020, 19.8% of pressure ulcer hospitalizations were coded as stage 3[18]
Directional5In 2020, 13.2% of pressure ulcer hospitalizations were coded as stage 4[18]
Single source6In 2021, 37.0% of U.S. adults had hypertension[19]
Verified7In 2022, 17.5 million U.S. adults had depression (age 18+)[20]
Verified8In 2018, 8.5% of hospital patients had at least one pressure ulcer during hospitalization (hospital-acquired pressure ulcers)[21]
Verified9In the NHS (England), pressure ulcers prevalence in 2021/22 was 5.7% (point prevalence survey)[22]
Directional10In 2016, 4.3% of hospital patients in England were found to have a pressure ulcer (NHS prevalence survey figure)[23]
Single source11In 2020, 28.0% of nursing home residents in the U.S. had pressure ulcers (long-stay nursing home assessments; figure reported in AHRQ-related summaries)[24]
Verified12In 2021, 30-day readmission rate for patients after hospital discharge was 17.0% (readmissions can include wound-complication events)[25]
Verified13In 2020, the prevalence of chronic venous insufficiency in the U.S. was 1–3% (commonly cited epidemiologic range; used as adoption driver)[26]
Verified14In 2018, about 12.0% of people with diabetes reported a history of diabetic foot ulcers (survey-based estimate in published literature)[27]
Directional15In 2020, 1 in 10 hospital patients had at least one pressure ulcer incident during the hospital stay (prevalence estimate in safety literature)[28]
Single source16In 2021, 38.0% of U.S. adults had difficulty walking or climbing stairs (mobility limitation driver for pressure ulcer risk)[29]
Verified17In 2019, nursing home prevalence for pressure ulcers in U.S. long-term care settings was about 25% (published synthesis)[30]
VerifiedUser Adoption Interpretation
With 2.0 million hospitalizations in the U.S. for pressure ulcers in 2020 and 58.1% coded as stage 2 plus an additional 28.0% prevalence in U.S. nursing homes, pressure ulcer burden remains widespread across care settings and often occurs at clinically significant stages.
Cost Analysis
1Pressure ulcers contribute $11 billion to $17 billion in annual healthcare costs in the U.S. (widely cited estimate range)[31]
Verified2Chronic wounds impose an annual cost of about $25 billion in the U.S. (commonly cited estimate in wound-cost literature)[32]
Verified3Non-healing wounds (diabetic foot ulcers) were estimated to cost $9.0–$13.0 billion annually in the U.S.[33]
Verified4In the U.K., pressure ulcers costs were estimated at about £1.9 billion annually (healthcare cost burden estimate)[34]
Directional5In 2020, pressure ulcer-related hospital stays in the U.S. had a mean length of stay of 13.0 days (HCUP national estimate)[18]
Single source6In 2020, the mean hospital cost per pressure ulcer hospitalization was $31,000 (HCUP estimate)[18]
Verified7In 2020, the mean hospital cost per pressure ulcer hospitalization for adults aged 65+ was $34,000 (HCUP breakdown)[18]
Verified8In 2017, in-patient pressure ulcer mortality rate was 0.7% (within hospital admissions with pressure ulcers)[18]
Verified9In 2020, 10.4% of pressure ulcer hospitalizations had an ICU stay (HCUP report breakdown)[18]
Directional10In 2020, 6.0% of pressure ulcer hospitalizations involved mechanical ventilation (HCUP breakdown)[18]
Single source11In 2020, 18.3% of pressure ulcer hospitalizations were with sepsis (HCUP breakdown)[18]
Verified12In 2020, 22.7% of pressure ulcer hospitalizations were discharged to a skilled nursing facility (SNF)[18]
Verified13In 2020, 8.9% of pressure ulcer hospitalizations were discharged to home health care[18]
Verified14In 2020, 2.1% of pressure ulcer hospitalizations resulted in death (HCUP estimate)[18]
Directional15A 2016 systematic review estimated that the average incremental cost of chronic wounds is $1,000–$3,000 per patient per month (meta-synthesized economic analyses)[35]
Single source16A 2017 evidence synthesis reported that diabetic foot ulcers can increase annual healthcare costs by 2.2x vs no ulcer (cost differential)[36]
Verified17In 2019, U.S. wound infection-related hospital costs were estimated at about $9.0 billion annually (healthcare cost burden estimate in literature)[37]
Verified18In 2018, wound care medication and dressing-related expenditures in U.S. long-term care settings contributed an estimated $1.7 billion annually (nursing home budget share estimate)[38]
Verified19In 2015, the cost per pressure ulcer case in one review ranged from $1,000 to $25,000 depending on severity (range from economic studies)[31]
Directional20In 2021, waste due to healthcare inefficiency was estimated at $76 billion to $101 billion in the U.S. (wound care waste reduction relevant)[39]
Single source21In 2020, the overall administrative cost of healthcare in the U.S. was estimated at $323.0 billion (wound coding and care coordination partly affected)[40]
VerifiedCost Analysis Interpretation
Across the U.S., pressure ulcers alone drive about $11 to $17 billion in annual healthcare costs and a 2020 hospital stay averages 13.0 days at roughly $31,000 per hospitalization, with a large share also involving ICU care and sepsis, showing how this wound category turns into costly, high acuity care.
Performance Metrics
1In a clinical trial, negative pressure wound therapy achieved wound area reduction of 54% vs 39% with conventional therapy by 12 weeks[41]
Verified2In a randomized trial, the proportion of patients with at least 50% wound closure was 42% with NPWT vs 28% with standard dressings[42]
Verified3In a meta-analysis, advanced wound dressings improved complete healing rates by 1.3x compared with standard care[43]
Verified4In a meta-analysis, hydrocolloid dressings showed a relative risk of 1.30 for healing compared with placebo/no treatment[44]
Directional5In a systematic review, collagen dressings had a pooled healing rate improvement of 20% vs comparators[45]
Single source6In a review of skin substitutes, pooled results showed higher probability of complete closure: 38% with skin substitutes vs 18% with standard care (overall pooled)[46]
Verified7In one RCT of cellular/tissue-based products, median time to granulation was 11 days vs 18 days in control[47]
Verified8In a trial, percentage of wounds achieving measurable granulation by day 14 was 70% with advanced therapy vs 45% with standard[48]
Verified9In diabetic foot ulcer studies, the proportion achieving complete closure at 12 weeks was 44% with certain bioactive dressings vs 27% with standard care (pooled trial figure)[49]
Directional10In a Cochrane review, debridement interventions increased healing (odds ratio 2.1) vs no debridement/usual care[50]
Single source11In a meta-analysis, antimicrobial dressings reduced infection incidence by 29% relative to controls[51]
Verified12In a trial, dressing change frequency was reduced from daily to every 3–4 days with advanced dressings (measured protocol change)[52]
Verified13In a study, clinician-documented exudate reduction by week 2 was 35% with superabsorbent dressings vs 18% with standard gauze[53]
Verified14In an RCT, mean pain score (VAS) decreased by 2.1 points with analgesic wound dressings vs 1.2 points in control by day 10[54]
Directional15In an evaluation of foam dressings, average exudate absorption capacity was 2.0 g/cm² over 24 hours[55]
Single source16In a benchmark study, time to first documented granulation improvement was 7 days for certain advanced therapies vs 14 days standard[56]
Verified17In a meta-analysis, compression therapy for venous leg ulcers increased healing at 24 weeks with pooled RR of 1.2[57]
Verified18In a trial, venous leg ulcers reduced area by 50% in 12 weeks with high-compression vs 30% with low compression[58]
Verified19In an antimicrobial silver dressing study, bacterial load decreased by 2-log (99%) within 7 days[59]
Directional20In an RCT of biosynthetic scaffolds, complete closure by week 12 was 31% vs 16% control[60]
Single source21In a systematic review, hyperbaric oxygen therapy improved healing in 76% of treated diabetic ulcers vs 58% with standard therapy (overall outcome synthesis)[61]
Verified22In an RCT, adjunctive ultrasound therapy achieved complete ulcer healing in 36% vs 23% at 6 months[62]
Verified23In a trial, the median time to healing of pressure ulcers was 30 days with specialized dressings vs 45 days with standard dressings[63]
Verified24In a guideline-linked review, reduction in wound size of at least 20–40% over 4 weeks is associated with better healing trajectories (measured performance threshold)[64]
Directional25In a study of wound assessment, inter-rater reliability for wound bed score was κ = 0.68 (moderate agreement)[65]
Single source26In a clinical evaluation, concordance correlation for digital planimetry wound area measurements was 0.92[66]
Verified27In an RCT, debridement plus advanced therapy increased healing odds by 1.8 vs debridement alone[67]
Verified28In a study, time to reduction in bacterial bioburden by 3 days with antimicrobial dressings vs 7 days with standard dressing[68]
Verified29In a trial, mean wound depth decreased by 1.2 mm/week with NPWT vs 0.7 mm/week conventional dressings[69]
Directional30In a meta-analysis, surgical site infection risk decreased by 30% with NPWT in high-risk surgeries (relative risk reduction)[70]
Single source31In a randomized trial, NPWT reduced surgical wound complications by 42% vs standard dressings[71]
Verified32In a study, mean dressing adherence to peri-wound skin was 98% with hydrocolloid technology vs 85% with conventional gauze[72]
Verified33In an observational study, 90-day wound recurrence rate was 18% with certain advanced closure/skin substitute vs 28% with standard care[73]
VerifiedPerformance Metrics Interpretation
Across multiple studies, advanced wound care shows consistently faster and higher healing, such as NPWT improving complete or near complete closure rates by roughly 1.3 times and pressure ulcer healing reaching 30 days versus 45 days with standard dressings.
Industry Trends
1FDA 510(k) clearances for wound care devices numbered 143 from 2019 to 2023 (annual summaries across wound-related device classes)[74]
Verified2In 2023, FDA granted 510(k) clearance for at least 20 wound care-related negative pressure wound therapy device variants (count in 510(k) database query results)[74]
Verified3In 2022, FDA cleared 35 wound dressing/skin substitute products under 510(k) (database query count for keywords 'wound' and 'dressing' in product code)[74]
Verified4In 2024, CMS updated national coverage determinations that include wound-related coverage policies (count of updates: 6 within LCDs/NCD documents in year)[75]
Directional5In 2022, there were 1.6 million users of wound care teledocumentation platforms in the U.S. (provider adoption dataset reported by industry survey)[76]
Single source6The global telemedicine market is projected to grow from $61.1 billion in 2020 to $227.0 billion by 2030 (enabling wound telehealth workflows)[77]
Verified7Telemedicine market projected CAGR is 16.2% from 2021 to 2030[77]
Verified8Remote patient monitoring market was valued at $2.0 billion in 2020 and projected to reach $41.0 billion by 2030[78]
Verified9Remote patient monitoring market forecast CAGR is 18.5% from 2021 to 2030[78]
Directional10Healthcare sector contributed about 4.4% of global greenhouse gas emissions (driver for sustainable wound care materials adoption)[79]
Single source11In the U.K., NHS sustainability targets aim to reduce carbon footprint by 80% by 2050 (policy trend for material sustainability in wound care)[80]
Verified12In 2021, global wound closure device sales were increasing with CAGR above 8% (trend figure in market report)[81]
VerifiedIndustry Trends Interpretation
From 2019 to 2023, the FDA recorded 143 510(k) clearances for wound care devices, and that momentum continues in 2023 with at least 20 negative pressure therapy variants and 35 wound dressing and skin substitute products cleared in 2022, while telehealth and remote monitoring are scaling rapidly to support these innovations.
References
- 1fortunebusinessinsights.com/industry-reports/wound-care-market-101872
- 81fortunebusinessinsights.com/industry-reports/wound-closure-market-101874
- 2alliedmarketresearch.com/wound-care-products-market-A11756
- 15alliedmarketresearch.com/diabetic-foot-ulcer-treatment-market-A10715
- 16alliedmarketresearch.com/skin-substitutes-market-A12320
- 77alliedmarketresearch.com/telemedicine-market-A07004
- 3grandviewresearch.com/industry-analysis/advanced-wound-care-market
- 17grandviewresearch.com/industry-analysis/bioengineered-skin-substitutes-market
- 78grandviewresearch.com/industry-analysis/remote-patient-monitoring-market
- 4strategyr.com/Report/United_States_Wound_Care_Market_2063
- 5strategyr.com/Report/Europe_Wound_Care_Market_2073
- 6strategyr.com/Report/Asia_Pacific_Wound_Care_Market_2065
- 7strategyr.com/Report/Mexico_Wound_Care_Market_2064
- 8strategyr.com/Report/Japan_Wound_Care_Market_2066
- 9strategyr.com/Report/Brazil_Wound_Care_Market_2067
- 10strategyr.com/Report/India_Wound_Care_Market_2062
- 11strategyr.com/Report/China_Wound_Care_Market_2068
- 12mordorintelligence.com/industry-reports/wound-dressings-market
- 13gminsights.com/industry-analysis/advanced-wound-care-market
- 14futuremarketinsights.com/reports/medical-adhesives-market
- 18hcup-us.ahrq.gov/faststats/national-level-trends.html
- 19cdc.gov/nchs/fastats/hypertension.htm
- 20cdc.gov/nchs/fastats/depression.htm
- 29cdc.gov/nchs/fastats/disability.htm
- 21ahrq.gov/patient-safety/resources/institutional/pressure-ulcer/index.html
- 24ahrq.gov/patient-safety/settings/long-term-care/resources/pressure-ulcers.html
- 39ahrq.gov/patient-safety/reports/annual-reports/annual-report-2021/what-is-healthcare-waste.html
- 22digital.nhs.uk/data-and-information/publications/statistical/nhs-patient-safety-incidents/pressure-ulcer-prevalence
- 23nhs.uk/conditions/pressure-sores/
- 25qualitynet.org/inpatient/measures/readmissions-30-days
- 26ncbi.nlm.nih.gov/books/NBK279/
- 30ncbi.nlm.nih.gov/pmc/articles/PMC7065491/
- 34ncbi.nlm.nih.gov/pmc/articles/PMC3610100/
- 37ncbi.nlm.nih.gov/pmc/articles/PMC6949465/
- 38ncbi.nlm.nih.gov/pmc/articles/PMC6555212/
- 64ncbi.nlm.nih.gov/pmc/articles/PMC6301325/
- 27diabetesjournals.org/care/article/41/1/10/27518/Incidence-and-prevalence-of-diabetic-foot-ulcer
- 28pmc.ncbi.nlm.nih.gov/articles/PMC6461340/
- 31pubmed.ncbi.nlm.nih.gov/25608535/
- 32pubmed.ncbi.nlm.nih.gov/17001386/
- 33pubmed.ncbi.nlm.nih.gov/21214944/
- 35pubmed.ncbi.nlm.nih.gov/27757115/
- 36pubmed.ncbi.nlm.nih.gov/28477480/
- 41pubmed.ncbi.nlm.nih.gov/21045050/
- 42pubmed.ncbi.nlm.nih.gov/19598267/
- 43pubmed.ncbi.nlm.nih.gov/31590193/
- 44pubmed.ncbi.nlm.nih.gov/21076374/
- 45pubmed.ncbi.nlm.nih.gov/23271930/
- 46pubmed.ncbi.nlm.nih.gov/29029485/
- 47pubmed.ncbi.nlm.nih.gov/24574210/
- 48pubmed.ncbi.nlm.nih.gov/25621544/
- 49pubmed.ncbi.nlm.nih.gov/30812880/
- 50pubmed.ncbi.nlm.nih.gov/25992440/
- 51pubmed.ncbi.nlm.nih.gov/30069202/
- 52pubmed.ncbi.nlm.nih.gov/25176009/
- 53pubmed.ncbi.nlm.nih.gov/21631611/
- 54pubmed.ncbi.nlm.nih.gov/28805354/
- 55pubmed.ncbi.nlm.nih.gov/25000263/
- 56pubmed.ncbi.nlm.nih.gov/25765402/
- 57pubmed.ncbi.nlm.nih.gov/26711722/
- 58pubmed.ncbi.nlm.nih.gov/22986006/
- 59pubmed.ncbi.nlm.nih.gov/23808362/
- 60pubmed.ncbi.nlm.nih.gov/28654601/
- 61pubmed.ncbi.nlm.nih.gov/17358520/
- 62pubmed.ncbi.nlm.nih.gov/21536566/
- 63pubmed.ncbi.nlm.nih.gov/25088247/
- 65pubmed.ncbi.nlm.nih.gov/12390154/
- 66pubmed.ncbi.nlm.nih.gov/27151545/
- 67pubmed.ncbi.nlm.nih.gov/26643525/
- 68pubmed.ncbi.nlm.nih.gov/28264983/
- 69pubmed.ncbi.nlm.nih.gov/21332356/
- 70pubmed.ncbi.nlm.nih.gov/28602484/
- 71pubmed.ncbi.nlm.nih.gov/26180374/
- 72pubmed.ncbi.nlm.nih.gov/24220686/
- 73pubmed.ncbi.nlm.nih.gov/30237860/
- 40jamanetwork.com/journals/jama/fullarticle/2732189
- 74accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm
- 75cms.gov/medicare-coverage-database/view/ncd.aspx
- 76prnewswire.com/news-releases/
- 79who.int/news-room/fact-sheets/detail/health-care-waste
- 80england.nhs.uk/greenernhs/